Pharmaceutical

Sable Therapeutics and Columbia sign deal on obesity treatments

Sable Therapeutics has signed an agreement with Columbia University to develop new polycation nanomedicines aimed at treating obesity.

Aug 13, 2024 - 04:00
Sable Therapeutics and Columbia sign deal on obesity treatments
Sable Therapeutics has signed an agreement with Columbia University to develop new polycation nanomedicines aimed at treating obesity.
Read the original article

Tags:

Previous Article

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

Next Article

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Congress’ negotiations over doc pay, health centers fell apart ahead of spending extension

STAT+: Congress’ negotiations over doc pay, health cent...

Jan 18, 2024

Atossa Therapeutics progresses Phase II preventative breast cancer therapy

Atossa Therapeutics progresses Phase II preventative br...

Jan 27, 2024

STAT+: Syndax’s leukemia drug succeeds in pivotal study

STAT+: Syndax’s leukemia drug succeeds in pivotal study

Oct 2, 2023